Insights about U.S. Stocks that landed in the Red-Zone during Wednesday’s trade, are depicted underneath:

Resolute Energy Corp (NYSE:REN)’s shares dwindled -5.71%, and closed at $0.990. The stock volatility for the week is 5.87%, while for the month remained 11.54%. The mean recommendation of analysts for this stock is 3.20. (where 1=Buy, 5=Sale).

Resolute Energy Corporation, an independent oil and gas corporation, attains, explores for, develops, and produces oil, gas, and hydrocarbon liquids.

Cumulus Media Inc (NASDAQ:CMLS), declined -5.44%, and closed at $3.13.

Cumulus Media Inc. (CMLS), declared operating results for the three months and year ended December 31, 2014.

Capital expenditures for the three months ended December 31, 2014 totaled $5.6 million, comprised of ongoing maintenance and upgrades across our broadcast platform. Capital expenditures during the three months ended December 31, 2013 were $2.6 million.

Results for Year Ended December 31, 2014:

On an actual basis, net proceed for the year ended December 31, 2014 raised $237.3 million, or 23.1%, to $1,263.4 million, contrast to $1,026.1 million for the year ended December 31, 2013. The raise resulted from raises of $178.7 million, $30.3 million, $16.2 million and $12.1 million in broadcast advertising, digital advertising, political advertising and license fees and other proceed, respectively. The broadcast advertising raise was primarily attributable to the addition of the operations of WestwoodOne, which was attained on December 12, 2013, and several new stations being operated under LMAs in Chicago and San Jose, CA. The raises were partially offset by decreases in local spot and national spot proceed. The raise in digital advertising was primarily due to raised Rdio user generation activity and digital commerce generated by our Sweetjack platform. The raise in political advertising proceed was due to additional activity associated with mid-term and gubernatorial elections in 2014, the even numbered year for elections.

On a pro forma basis, net proceed for the year ended December 31, 2014 raised $17.7 million, or 1.4%, to $1,263.4 million, contrast to $1,245.7 million for the year ended December 31, 2013. The raise resulted from a decrease of $39.2 million in advertising and raises of $28.0 million, $16.0 million and $12.9 million in digital advertising, political advertising and license fees and other proceed, respectively. Net broadcast advertising proceed was down due to an ongoing weakness in several large local markets. The raise in digital advertising proceed was primarily due to raised Rdio user generation activity. Political advertising raised due to additional activity associated with mid-term and gubernatorial elections in 2014, the even numbered year for elections.

Cumulus Media Inc. (CMLS) combines high-quality local programming with iconic, nationally syndicated media, sports and entertainment brands in order to deliver premium choices for listeners, provide substantial reach for advertisers and create opportunities for shareholders.

Ibio Inc (NYSEMKT:IBIO), dipped - 5.38%, and closed at $0.875.

Formerly on February 25, iBio, Inc. (IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, recently declared the issue of US patent serial No. 8,962,278 titled “COMPOSITIONS AND METHODS FOR PRODUCTION OF IMMUNOGLOBULINS.” The patent will join patent family members formerly issued in China, India, Korea and Europe.

“This technology continues the expansion of iBio’s antibody portfolio and broadens our patent protection for product candidates addressing anthrax, both for natural outbreaks and for possible biodefense considerations,” said Wayne P. Fitzmaurice Ph.D., iBio’s Vice President, Intellectual Property.

Claims involve human monoclonal antibodies specifically recognizing the Protective Antigen (PA) or the Lethal Factor (LF) of Bacillus anthracis, the bacteria causing anthrax. In mouse and non-human primate studies such antibodies, produced with the use of iBio’s iBioLaunch™ gene expression platform technology, prevented death in 100% of animals given an otherwise lethal doses of anthrax spores.

In addition to its proprietary fibrosis therapeutic program and the production of monoclonal antibody candidates, iBio is exploring the commercialization of its iBioLaunch gene expression platform technology for viral and bacterial infectious disease applications through collaborations with third parties. The corporation’s technology has been successfully applied to the development of an anthrax vaccine candidate, and a Phase 1 clinical trial of the safety and immunogenicity of this experimental vaccine, produced at the Fraunhofer USA Center for Molecular Biotechnology under a research license from iBio, is being conducted at Walter Reed Army Institute of Research. The clinical trial is projected to be accomplished in July 2015 (ClinicalTrials.gov Identifier: NCT02239172). Funding for this vaccine program was awarded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, in December 2012.

iBio is developing a proprietary product, IBIO-CFB03, for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis, and other fibrotic diseases using its iBioLaunch™ gene expression platform.

Seventy Seven Energy Inc (NYSE:SSE), dropped -5.27%, and closed at $4.31.

Seventy Seven Energy Inc. (SSE), stated financial and operational results for the 2014 full year and fourth quarter. Key information related to the 2014 full year is as follows:

• Adjusted Proceeds were $1.978 billion on Total Proceeds of $2.081 billion.
• Adjusted EBITDA was $446.2 million.
• Net loss per fully diluted share was ($0.17).
• Proceed diversity raised 9% to 19% of merged proceeds from 2013 full year to 2014 full year.

SSE stated total proceeds of $2.081 billion for the 2014 full year, a 5% decrease contrast to total proceeds of $2.188 billion for the full year 2013.

Total proceeds for the fourth quarter of 2014 were $494.9 million, a 6% decrease contrast to total proceeds of $526.8 million for the third quarter of 2014 and adjusted proceed of $460.8 million for the fourth quarter of 2013. Adjusted EBITDA for the fourth quarter of 2014 was $107.1 million, contrast to $132.8 million for the third quarter of 2014 and $103.9 million for the fourth quarter of 2013.

“We are happy with our 2014 results, but it is evident that 2015 is going to be one of the most challenging years our industry has seen in quite some time,” Chief Executive Officer Jerry Winchester said. “As we practiced in our hydraulic fracturing segment during the fourth quarter, we expect to see market volatility and pricing pressure across all of our businesses in 2015.”

For the fourth quarter of 2014, the drilling segment contributed proceeds of $204.5 million and Adjusted EBITDA of $87.4 million, contrast to $200.4 million of proceeds and Adjusted EBITDA of $82.4 million for the third quarter of 2014 and proceeds of $178.5 million and Adjusted EBITDA of $66.9 million for the fourth quarter of 2013. The improved financial performance for the fourth quarter of 2014 contrast to the third quarter of 2014 was partially aided by four new PeakeRigs™ delivered in the fourth quarter of 2014.

SSE is a diversified oilfield services corporation that provides a wide range of wellsite services to U.S. land-based E&P customers. SSE offers services and equipment that are planned to our customers’ oil and natural gas operations.